|
Erich Veigel joined the MJ team as an employee benefits consultant in our Benefits Consulting department. Erich has since transitioned into the role of client executive and has added the designation of director of client experience to his repertoire. Erich’s experience has made him an expert in wellness, benefits technology, plan design analysis, network analysis, Rx program analysis, as well as strategic planning and execution.
In his role, Erich leads a group of client executives while being responsible for ensuring the delivery of our value proposition and exceptional client experience. He also develops and executes employee benefits strategies for large group clientele.
Related Blogs
Health Care Industry Trends to Watch in 2026
The MJ CompaniesHealth care organizations enter 2026 facing numerous operational, financial and liability pressures, including labor shortages, inflation, supply chain volatility and the impact of U.S. ...
Read More
2025 Ended with Softest Market Conditions Since 2017 for all Account Sizes & Majority of Lines of Business, The Council’s P/C Market Survey Shows
The MJ CompaniesThe market appeared to move further into the soft part of the insurance market cycle in Q4 2025. Premiums across all account sizes rose ...
Read More
Miles for Miles Helps People With Intellectual and Developmental Disabilities Thrive
Britni ShroutMiles Peck loves school as much for the chance to spend time with his friends as for the classroom experience. He is bracing his ...
Read More
EBSA Updates National Employee Benefit Plan Enforcement Projects for 2026
DeAnn DeckThe Employee Benefits Security Administration (EBSA) announced updates to its national enforcement projects for fiscal year 2026. According to EBSA, these projects highlight areas ...
Read More
The Hard Market Is Shifting—Here’s What That Means for YOU
Adam AdlerFor years, organizations have been told the same thing at renewal: higher costs, fewer options, and little room to negotiate. Now, that message is ...
Read More
Employer Response to Pharma Shifts
Chris AntypasVolatility in the pharmaceutical industry, including the expanding specialty drug pipeline, increased utilization of GLP-1 medications, and persistent supply chain disruptions, are contributing to rising costs ...
Read More